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S and I represent the proportion of the population susceptible and infectious, respectively.
U represents the proportion dead and recovered, with the number dead dependent on the
speci®c case fatality rates given in the data sets. The contacts of cases are divided into the
following classes: En the number of untraced latent individuals in the population, Ei the
number of traced latent contacts, and Ci the number of traced uninfected contacts. The
®nal class of contacts are those untraced and uninfected and so effectively remaining in
S. Q represents the proportion in quarantine and V the proportion protected by
vaccination. The average rate at which latent individuals become infectious13,21 is
a  latency period21  0:0685 days21 and the rate at which infectious individuals in
the community recover or die22 is g  infectious period21  0:116 days21. Two states of
quarantine are de®ned: the ®rst for the traced contacts successfully vaccinated and released
into the community at a rate x1, and the second for the infectious cases, which enter U at a
rate x2. Different vaccine ef®cacies are assumed for those uninfected, e1, and infected, e2.
The proportion of contacts found through contact tracing is r and the daily rate at which
infectious individuals enter quarantine from the community is v. The proportion of
contacts infected is de®ned as J. The rate at which potentially infected contacts occur is






Additional assumptions are that no transmission occurs from those quarantined, dead or
recovered and the background mortality rate was assumed to be negligible over the time
periods examined.
For the Boston, Burford, Warrington and Chester data sets, r  v  0, which effectively
reduces equations (1) above to a simple SEIR model9. Intervention parameters were only
required when equations (1) was ®tted to the data from Kosovo. Here, interventions were
implemented 31 days after the onset of symptoms in the index case1 with the associated
parameters shown in Table 2. The number of potentially infected contacts per case was
determined as 50 (ref. 1). Values of R0 were derived for each outbreak by minimizing the
mean square error between the mortality data and the predictions of mortality from the
model, while applying the outbreak-speci®c case fatality rates to U and adjusting R0 and
time of onset of symptoms in the index case. In the case of Kosovo, equations (1) were
®tted more simply to the reported number of cases rather than deaths. All the other
parameters required for equations (1) were obtained independently from the published
source(s) given in Table 1. For epidemics in London, R0 was roughly calculated from the
interepidemic interval, T  2pLD  D9=R0 2 1
1=2, where L is life expectancy between
1840 and 1870 adjusted for excess births over deaths, equal to 25 years, and D  D9 is
latent  infectious period, equal to 0.063 years9.
Estimation of current vaccination coverage
Given that smallpox vaccination ceased in industrialized countries in the mid to late 1970s
(ref. 13), a crude estimate of the immunity of the contemporary UK population was
calculated, on the basis of 50% having been vaccinated as infants up to 1972, and
estimating that about 60% of these would be alive today from current population statistics.
Of these only about 60% would still be protected by the vaccinations done on average 50
years previously, calculated by extrapolating from data on secondary attack rates, which
increased from 4 to 12% over 10 years following vaccination23. This suggests that the level
of herd immunity may be about 18%, which will continue to decrease with time.
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Vaccines rarely provide full protection from disease. Nevertheless,
partially effective (imperfect) vaccines may be used to protect
both individuals and whole populations1±3. We studied the poten-
tial impact of different types of imperfect vaccines on the evolu-
tion of pathogen virulence (induced host mortality) and the
consequences for public health. Here we show that vaccines
designed to reduce pathogen growth rate and/or toxicity diminish
selection against virulent pathogens. The subsequent evolution
leads to higher levels of intrinsic virulence and hence to more
severe disease in unvaccinated individuals. This evolution can
erode any population-wide bene®ts such that overall mortality
rates are unaffected, or even increase, with the level of vaccination
coverage. In contrast, infection-blocking vaccines induce no such
effects, and can even select for lower virulence. These ®ndings
have policy implications for the development and use of vaccines
that are not expected to provide full immunity, such as candidate
vaccines for malaria4.
Previous studies on the evolution of vaccine resistance have
focused on the spread of `escape' mutants that display epitopes
different to those in the vaccine, thereby escaping immune recogni-
tion5±7Ðthis has already happened for polio8 and hepatitis B9. New
vaccines may eventually get around this problem by, for example,
targeting conserved epitopes or multiple epitopes simultaneously.
Here we study an alternative counter-adaptation to vaccination
involving pathogen life-history traits, namely virulence (induced
host mortality) and transmission rate. To address this issue we
incorporated standard evolutionary theory for virulence evolu-
tion10±12 into an epidemiological framework1.
We begin with an analysis of the evolution of parasite virulence
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(the disease-induced mortality rate of the host) in a homogeneous
host population. We do this by studying the ability of a rare mutant,
with virulence denoted a*, to invade a population of resident
parasites with virulence a (the asterisk distinguishes the mutant's
trait from the resident's). The evolutionarily stable (ES) pathogen
virulence can be found by maximizing the mutant pathogen's
R0[a*,a] at a  a*. (See equation (1) below.) When the host
population is homogeneous and has reached epidemiological equi-
librium (as denoted by the circum¯ex accent (`hat' symbol)
throughout), the expression for the mutant's ®tness is given by
the expected number of secondary cases produced by a single host
infected by this mutant over its entire infectious period10±13:
R0a*;a 
b*Ãx  jÃy
d  a*  x*  jÃh
1
where x and y are the densities of uninfected and infected hosts,
respectively, b is the pathogen's transmission rate, h  by is the
rate at which hosts acquire new infections (termed `the force of
infection'), x is the pathogen's clearance rate (rate at which the host
becomes non-infectious), d is the host's natural mortality rate, and
j is the ef®ciency with which the pathogen invades an already
infected host (superinfection) relative to invading an uninfected
host13,14. The superinfection parameter, j, can also be modelled as
a function of virulence13, but here, for simplicity, we assume it to
be a constant. It is assumed that superinfecting parasites immedi-
ately replace the strain already present in the host: thus sh is the
rate at which the pathogen is cleared from the host due to arrival
of another strain. Note that hÃ is determined by the resident
pathogen strain. Thus, by setting the density of infected hosts to
zero, we recover the classical de®nition of R0, which allows us to
tell whether the mutant pathogen can invade a fully susceptible
host population1.
Here we assume, as in classical models of the evolution of
virulence10±14, that the pathogen ®tness function in equation (1)
includes trade-offs involving pathogen virulenceÐthat is, virulence
has bene®cial, pleiotropic effects on other pathogen life-history
traits that offset the ®tness cost of host death (which prematurely
ends the infectious period). Two types of virulence bene®ts
have been proposed. First, transmission rate is assumed to be an
increasing function of pathogen virulence. Second, clearance rate is
assumed to be slower with higher virulence. The net result of these
negative and positive in¯uences on pathogen ®tness is that there is
an intermediate optimum level of virulence that maximizes ®tness.
Although there are few data testing these assumed ®tness relation-
ships in pathogens, they are generally supportive10,15,16. The exact
nature of these relationships will depend on the biology of each
particular host±pathogen interaction, but here we de®ne these
trade-offs in simple forms by:
b  ba  b1a
b2
x  xa  c1a
2c2
2
where the coef®cients with subscripts are constants that determine
the shape of the trade-offs, and hence the value of a that maximizes
®tness.
The question now is how does host immunity (or `resistance')
change the optimum virulence relative to that in a completely non-
immune (`susceptible') host population? Still assuming a homo-
geneous host population, we consider four different forms of
immunity, with ef®cacies denoted r1, r2, r3 and r4, which indepen-
dently affect different stages of the pathogen's life cycle (Fig. 1). The
®rst is anti-infection immunity, which decreases the probability that
a host becomes infected. The second is anti-growth-rate immunity,
which directly reduces virulence and concomitantly affects trans-
mission rate and host recovery. The third is transmission-blocking
immunity, which only decreases parasite transmission. The fourth is
anti-toxin immunity which directly reduces virulence but, contrary
to anti-growth-rate immunity, does not affect parasite transmission
and host recovery rates. This yields:
a9  1 2 r21 2 r4a
b9  1 2 r3b1 2 r2a
x9  x1 2 r2a
h9  1 2 r1b9y9
3
where the prime pertains to immune hosts. Assuming that only the
trade-off between virulence and transmission is operating (clear-
ance rate, x, is a constant), yields the ES virulence:
a* 
b2d  x  jh1 2 r11 2 r3
1 2 b21 2 r21 2 r4
4
Note that, throughout, virulence is measured as induced host
mortality in susceptible (non-immune) hosts. Equation (4) implies
that anti-growth-rate and anti-toxin immunity (modelled by r2 and
r4) always select for higher virulence. This is because they reduce the
risk of host death and hence selection against more virulent
mutants. Indeed, evolution will restore the virulence observed in a
uniform population of resistant hosts, as well as the force of
infection, to that observed in a uniform population of susceptible
hosts by increasing intrinsic virulence (that is, virulence as meas-
ured in susceptible hosts). Thus a pathogen following a strategy that
would generate optimal virulence in a resistant host will induce a
higher-than-optimal virulence in a susceptible host17. In contrast,
anti-infection (r1) and transmission-blocking (r3) immunity select
for lower virulence whenever there is superinfection, and leave it
unchanged otherwise. They act indirectly on the evolution of
parasite virulence via the force of infection through their effects
on the rate at which an infection is prematurely ended by the arrival
of a superinfecting pathogen14,17. Although equation (4) de®nes the
ES virulence as a function of the force of infection, which is itself a
function of virulence, the results discussed above can be rigorously
proven using implicit differentiation analysis (not shown).
If we alternatively assume that there is only a trade-off between







In this case, anti-growth and anti-toxin immunity increase viru-
lence, and the other two forms of immunity have no effect. When
both trade-offs are included, the conclusions derived from equation
Infection Growth Transmission
r1 r2 r3
Figure 1 Schematic representation of the action of different types of host resistance at
different stages of the pathogen's life cycle. r1, anti-infection resistance; r2, anti-growth-
rate resistance; r3, transmission-blocking resistance. A fourth type of resistanceÐanti-
toxin resistance, r4Ðis not shown because it only acts upon host death rates.
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(4) do not qualitatively change.
What, then, if the pathogen faces a heterogeneous population of
susceptible and resistant hosts, as would happen if a vaccination
programme was implemented? On the one hand, we have shown
that the consequences of vaccinating individual hosts is to select for
higher levels of intrinsic virulence in the case of anti-growth-rate
and anti-toxin vaccines. On the other hand, immunized hosts will
transmit less, die less and recover more quickly than non-immune
hosts, thus reducing the overall level of disease in the population.
We now allow this epidemiology to feed back into the pathogen's
virulence evolution, and vice versa, in order to determine the overall
impact of vaccination programmes on the health of the population.
The epidemiological model that we used was a modi®ed version of
the standard susceptible-infected model1 with two classes of
hostsÐthose that are fully susceptible to the pathogen, and those
that are partially immune. In addition, we assume a continuous
vaccination procedure which provides imperfect but life-long
immunity. It is written as:
dx=dt  1 2 f l 2 d  hx  xy
dx9=dt  f l 2 d  h9x9  x9y9
dy=dt  hx 2 d  a  xy
dy9=dt  h9x9 2 d  a9  x9y9
6
where l is a constant rate of ¯ow (which covers both reproduction
and immigration) of uninfected hosts into the population, among
which a fraction f are resistant, that is, vaccinated, and the forces of
infection on susceptible and resistant hosts become h  by  b9y9
and h9  1 2 r1h, respectively. Note that there are no terms for
superinfection in equation (6) as these cancel out. For simplicity, we
assume that resistant hosts do not lose immunity to become
susceptible, and, except by vaccination, susceptible hosts do not
acquire immunity. This latter assumption is relaxed in our malaria
example below.
As for the simple homogeneous case, the ES parasite virulence is
found by maximizing at a  a*:
R0a*;a 
b*Ãx  jÃy
d  a*  x*  jÃh

b9*1 2 r1Ãx9  jÃy9
d  a9*  x9*  jÃh9
7
which can be seen as a weighted average of the per-host transmission
factors18 on susceptible and resistant hosts (see Supplementary
Information). Equations (6) and (7) can then be solved jointly to
yield the ES virulence and population prevalence of disease once
evolution has occurred.
A numerical example shows that as the ef®cacy of anti-growth-
rate and anti-toxin vaccines increases, there is a marked increase in
virulence (Fig. 2a). An exception occurs for very high ef®cacy anti-
growth-rate vaccines, because the contribution to ®tness from
vaccinated individuals becomes very small (see Supplementary
Information). ES virulence always increases with the ef®cacy of
anti-toxin vaccines, because this type of vaccine removes the cost of
virulence (increased mortality) without affecting its bene®t
(increased transmission). Consequently, the ®tness contribution
of vaccinated hosts always increases with the ef®cacy of an anti-
toxin vaccine. In contrast, as the ef®cacy of anti-infection and anti-
transmission vaccines increases, pathogens will evolve lower levels
of virulence if superinfection occurs (Fig. 2a). This is because these
vaccines reduce superinfection rates. When pathogens are less likely
to be competitively excluded, the bene®ts of keeping the host alive
are greater. The reduction in virulence is weaker for transmission-
blocking vaccines than for infection-blocking vaccines because,
with transmission-blocking vaccines, vaccinated hosts are fully
susceptible to infection. Consequently, the force of infection is
higher and this selects for higher virulence levels. When vaccines
are fully effective (`perfect'), all except the anti-toxin vaccines share
the same ES virulence. When superinfection occurs, this level falls
below the virulence reached when vaccines are never used (or are
totally ineffective). This is because, with a perfect vaccine, vacci-
nated hosts do not transmit the disease and, through the decrease of
the force of infection, serve to indirectly favour lower virulence17,19.
A perfect anti-toxin vaccine (a vaccine that completely removes the
deleterious effects of the parasite on its host) does not decrease
transmission and always selects for extreme intrinsic virulence
(Fig. 2a).
In addition to virulence consequences, vaccination changes dis-
ease prevalence. Figure 2b shows that as vaccination coverage
increases, anti-infection and anti-transmission vaccines always
reduce disease prevalence when pathogen evolution occurs, and
can sometimes eliminate the disease. Anti-growth-rate vaccines, on
the other hand, have hardly any effect on prevalence because of a
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Figure 2 Evolutionary and epidemiological consequences of using different types of
vaccines. The different coloured solid curves represent the ®rst three types of vaccines
(see Fig. 1), and the red dashed line is for anti-toxin vaccines. a, Evolutionarily stable (ES)
parasite virulence (measured on susceptible hosts) plotted against the ef®cacy of the
vaccine. b, Parasite prevalence (fraction of infected hosts) plotted against the proportion
of vaccinated hosts. The horizontal black lines show the outcome in the absence of
vaccination. In a, b1 = 0.5 and f = 0.2 (see text for de®nitions of b1 and f ). In b,
b1 = 0.2 and ef®cacy (r1, r2, r3 or r4) is 0.9. Other parameter values (see text for de®nitions)
are: l = 25, d = 1, j = 1, b2 = 0.2, c1 = 0 (that is, no relationship between recovery rate
and virulence).
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reduced transmission due to the direct effect of the vaccine and
increased transmission through the evolution of higher virulence in
vaccinated hosts. Anti-toxin vaccines may be even worse. Because
these vaccines do not reduce transmission rate, increased vaccina-
tion coverage can increase pathogen prevalence above pre-vaccina-
tion levels.
The above evolutionary analysis assumes that hosts and patho-
gens are in population dynamic equilibrium. Extensive numerical
simulations indicate that our model generates simple dynamics of
rapid approaches to a stable point equilibrium. Many diseases,
however, have more complex epidemiological dynamics, which may
exhibit cycles or chaotic behaviour. Even if there is a point attractor,
the transient dynamics following vaccination may be so pro-
nounced or so long-lasting that an analysis based on equilibrium
conditions may be irrelevant. In these situations, the selective
pressures would vary both in space (from one host to another)
and time, and the evolutionary analysis would need to take into
account the effects of such variability on the invasion exponent of a
mutant parasite20.
Although a single epidemiological equilibrium exists, the evolu-
tionary analysis of our model revealed that there could be different
evolutionary outcomes depending on the initial conditions. Such
evolutionary bistability emerges when the parasite can take an
evolutionary route that leads to specialization on either susceptible
or resistant hosts (leading to low or high virulence, respectively).
However, our predictions regarding the effects of imperfect
vaccines are not qualitatively altered by evolutionary bistability.
This result has potentially important implications for the evolution
of specialization21,22 and for the evolution of multihost pathogens23,
but further exploration of this phenomenon falls outside the scope
of the present Letter.
Can the above general theory for a virtual pathogen contribute to
the rational design of vaccines against real pathogens such as
malaria parasites? Current efforts to develop a malaria vaccine are
focused on three different stages of the parasite's life cycleÐthe pre-
erythrocytic stages (sporozoites and liver-stage parasites), asexual
blood-stage parasites (merozoites and infected erythrocytes) and
the mosquito-stage parasites (gametocytes, gametes, ookinetes)4.
Immunity against these three stages corresponds to the anti-infec-
tion, anti-growth-rate and transmission-blocking forms of resis-
tance studied here. Anti-toxin malaria vaccines are also being
explored24. Using a modi®ed form of the general model to incorpo-
rate two important features of malaria epidemiologyÐnaturally
acquired immunity and vector transmission (see Supplementary
Information)Ðwe evaluated the public health consequences of
using various vaccines.
The model was parameterized using values typical of year-round
endemic Plasmodium falciparum malaria in a high transmission
area. Figure 3a±e shows that, as for the general model, the malaria
model predicts that anti-growth-rate and anti-toxin vaccines select
for higher virulence, while anti-infection vaccines select for lower
parasite virulence. In the malaria model, however, transmission-
blocking vaccines may favour slightly higher virulence (Fig. 3c).
This vaccine reduces transmission and, consequently, the reproduc-
k l m n o
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Figure 3 Predicted effects of anti-malaria vaccination coverage on virulence. a±e, The
probability of dying due to malaria in naive hosts, aN /(aN + xN + d). f±j, the prevalence of
malaria (yN + yI + yV). k±o, The total (population-wide) disease-induced mortality
(population average virulence weighted by prevalence of the different host types, given in
number of deaths per thousand per year). These results are for an example of endemic
malaria; predictions are shown not allowing (dashed line) and allowing (full line) parasite
evolution. We show the effects of single type vaccines and a combination vaccine under
the assumption that the different types of vaccines have the same level of ef®cacy as that
provided by natural immunity: r1 = r1 = 0.8, r2 = r2 = 0.8, r3 = r3 = 0.8, r4 = r4 = 0.8.
See Supplementary Information for symbol de®nition and further details on the malaria
model.
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tive value of parasites infecting vaccinated hosts. In this case,
evolution becomes mainly driven by the selective pressures occur-
ring in naturally immune hosts. This explains the increase in
virulence in spite of the indirect effect of superinfection acting in
the opposite direction (equation (4)). We also examined the
evolutionary consequences of a combination of different types of
vaccines. The use of a vaccine combining the four different types
also favours higher pathogen virulence despite the bene®cial effect
of anti-infection vaccines (Fig. 3e).
With or without evolution of the pathogen, vaccination is
expected to affect the prevalence of malaria. As in the general
model (Fig. 2b), the use of anti-infection and transmission-blocking
vaccines reduces the force of infection and consequently malaria
prevalence (Fig. 3f, h). In contrast, anti-growth-rate and anti-toxin
vaccines have hardly any effect on prevalence (Fig. 3g, i). A
combination vaccine, via the anti-infection and transmission-
blocking effects, is the most ef®cient in reducing malaria prevalence,
and could even lead to eradication for extreme vaccine coverage
(Fig. 3j).
The total number of deaths due to malaria depends on both
malaria virulence and on the prevalence of infection in the different
types of hosts. Figure 3k±o presents the consequences of vaccina-
tion at the level of the whole host population. In the absence of
pathogen evolution, not surprisingly, all the different types of
vaccines decrease the total disease mortality. However, with anti-
growth-rate, anti-toxin and transmission-blocking vaccines, evolu-
tion towards higher virulence (Fig. 3b±d) erodes the overall bene®ts
of vaccination (Fig. 3l±n). In contrast, when anti-infection vaccines
are used, evolution towards lower virulence (Fig. 3a) may increase
the population-level bene®ts of vaccination (Fig. 3k). At high
vaccination coverage, a vaccine that incorporates all four types of
vaccines would be the most ef®cient, even when evolution occurs
(Fig. 3o). This result supports the development of multivalent,
multi-stage vaccines which, it is hoped, will provide greater overall
protection than single-target vaccines4. Our ®nding that anti-
infection vaccines may have favourable effects on virulence evolu-
tion also strongly supports the use of other partially effective control
methods (for example, bed nets, mosquito control) to enhance the
long-term bene®ts of vaccination.
How long might such virulence evolution take? Given that genetic
variation exists for pathogen virulence10,15,16,25,26, one might expect
that, like the evolution of vaccine and drug resistance, the evolution
of virulence would occur on timescales that are relevant to public
health (decades or less). As an explicit example, we used the malaria
model to track the spread of a virulence mutant through time
following the start of a vaccination campaign. At 90% vaccine
coverage with an anti-growth-rate vaccine of 80% ef®cacy, it took
38 years for a mutant more than twice as virulent to increase from
1% to 50%, after which it spread towards ®xation very rapidly (see
Supplementary Information). Numerical simulations, however,
indicate that the speed of invasion is very sensitive to the shape of
the trade-off function. Accurate predictions of both the invasion
dynamics of a virulence mutant and of the evolutionary outcome
require further investigation of the shape of these trade-off
functions.
Purely epidemiological models have demonstrated that vaccines
which are protective for individuals in clinical trials can nonetheless
generate unwelcome consequences for a population as a whole2,3.
Our incorporation of evolution into the analysis shows that clini-
cally detrimental or bene®cial evolution can also occur. The direc-
tion of virulence evolution depends critically on the type of vaccine,
with several types promoting evolution that increases mortality risk
to individual hosts. However, virulence management (an applica-
tion of darwinian medicine27,28) requires speci®c models to answer
questions regarding speci®c biological systems. Using malaria as an
example, we found that the wide-scale use of even reasonably
effective anti-growth-rate and transmission-blocking vaccines
may ultimately do little to relieve community disease levels in
malaria-endemic areas. Moreover, the evolution prompted by
anti-growth-rate and anti-toxin vaccines can substantially increase
the risk for non-immune individuals, such as unvaccinated children
and non-immune travellers. The widespread use of such vaccines
thus raises dif®cult ethical issues. Nevertheless, it is probable that
anti-disease vaccines (anti-growth-rate and anti-toxin) will be
used widely for their short-term bene®cial effect at the individual
level.
Like drug resistance, the clinically detrimental evolution that we
are discussing here will occur on timescales longer than those of
clinical trials. Marked increases in virulence of some viral diseases
have already followed widespread use of anti-growth-rate vaccines
in the chicken industry29. When human populations become
uncontrolled experimental systems, we recommend that at the
very least, intrinsic virulence of the pathogen population (or
more realistically, putative virulence determinants such as in vitro
multiplication rates30) be closely monitored. M
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Microbial infection activates two distinct intracellular signalling
cascades in the immune-responsive fat body of Drosophila1,2.
Gram-positive bacteria and fungi predominantly induce the Toll
signalling pathway, whereas Gram-negative bacteria activate the
Imd pathway3,4. Loss-of-function mutants in either pathway
reduce the resistance to corresponding infections4,5. Genetic
screens have identi®ed a range of genes involved in these intra-
cellular signalling cascades6±12, but how they are activated by
microbial infection is largely unknown. Activation of the trans-
membrane receptor Toll requires a proteolytically cleaved form of
an extracellular cytokine-like polypeptide, SpaÈtzle13, suggesting
that Toll does not itself function as a bona ®de recognition
receptor of microbial patterns. This is in apparent contrast with
the mammalian Toll-like receptors14 and raises the question of
which host molecules actually recognize microbial patterns to
activate Toll through SpaÈtzle. Here we present a mutation that
blocks Toll activation by Gram-positive bacteria and signi®cantly
decreases resistance to this type of infection. The mutation
semmelweis (seml) inactivates the gene encoding a peptidoglycan
recognition protein (PGRP-SA). Interestingly, seml does not affect
Toll activation by fungal infection, indicating the existence of a
distinct recognition system for fungi to activate the Toll pathway.
To isolate new genes implicated in the Drosophila immune
response, we screened the ®rst chromosome for mutations that
inactivate genes involved in the control of the challenge-induced
expression of the antimicrobial peptides Diptericin and Drosomy-
cin. diptericin expression is controlled by the Imd pathway, whereas
induction of drosomycin is dependent on the Toll pathway4,5. From
2,500 independent lines, we isolated a mutant line in which the
ability to express drosomycin in response to infection by Gram-
positive bacteria (Micrococcus luteus, Streptococcus faecalis, Bacillus
thuringiensis) was abolished or severely reduced (Fig. 1a and data
not shown). We named this mutation semmelweis (seml) after Ignaz
Philipp Semmelweis, a Hungarian physician who was a pioneer in
the ®eld of antiseptic treatments and discovered the cause of
puerperal fever15. Expression of diptericin by Gram-negative bac-
teria (Escherichia coli, Erwinia carotovora carotovora and
Enterobacter cloacae; Fig. 1b and data not shown) was unaffected
in seml mutant ¯ies but abolished in two mutants of the Imd
pathway7,8, key and dredd (Fig. 1b). These phenotypes of seml in
response to challenges by various microorganisms are similar to
those of loss-of-function mutants of the Toll pathway5,6 (spz, Dif)
but distinct from mutations affecting the Imd pathway.
In addition to its Toll-dependent induction by Gram-positive
bacteria, drosomycin expression in the fat body is also activated by
fungal infection in a Toll-mediated process5. When challenging seml
¯ies with the entomopathogenic fungus Beauveria bassiana, we
noted that drosomycin expression was wild type, in contrast to
the results obtained with spz and Dif mutants, in which fungal
induction of drosomycin was nearly abolished (Fig. 1c). seml is
therefore the ®rst described Drosophila mutation that speci®cally
impairs the Toll-dependent induction of drosomycin by Gram-
positive bacteria without affecting that induced by fungal infection.
We next analysed the resistance of seml mutants to infections by
various microorganisms. We compared the data with those
obtained with spz and key mutants. The results (Fig. 2) show that
seml mutants are highly susceptible to Gram-positive infection
(Bacillus megaterium, S. faecalis), but are as resistant as wild-type
¯ies to fungal (B. bassiana) and Gram-negative bacterial infection
(E. coli, E. c. carotovora). As expected, in these experiments key ¯ies
were susceptible only to Gram-negative infection8, and spz mutants
both to fungal and Gram-positive infections5.
The similarities between the antibacterial responses in seml, spz
and Dif mutants prompted us to study the epistatic relationship
between seml and the Toll pathway components. We ®rst tested
whether seml was genetically upstream or downstream of Toll, using
the Toll10b gain-of-function allele, which leads to a challenge-
independent expression of drosomycin. The levels of drosomycin
transcription in Toll10b and seml; Toll10b ¯ies were similar (Fig. 3a),
indicating that seml is genetically upstream of Toll. We used the
same strategy to analyse the relationship between seml and the
serine protease inhibitor nec. A loss-of-function mutation in the nec
gene results in challenge-independent expression of drosomycin and
in the formation of melanotic spots on the cuticle13. Both pheno-
types are mediated by spz and Toll. Both nec and seml; nec ¯ies
express drosomycin in the absence of immune challenge and exhibit
melanotic spots (Fig. 3b, c). These results suggest that the seml
mutation inactivates a protein acting upstream of the Toll receptor
and of the protease cascade necessary to activate its ligand Spz
through proteolytic cleavage. In contrast to Toll-pathway mutants,





























Figure 1 Expression of antimicrobial peptides in different mutant backgrounds after
infection by fungi, Gram-positive or Gram-negative bacteria. Northern blots were
performed with total RNA from wild type (WT) ¯ies, seml mutant ¯ies, or ¯ies mutant
for genes in the Toll signalling pathway (spzrm7, Dif2) and in the Imd pathway (key4,
dreddD55). The ¯ies were infected with M. luteus (a), E. coli (b) or B. bassiana
(c) and incubated for 24 h at 25 8C before RNA preparation. rp49 is used as an RNA
loading control. n.i., not induced; drs, drosomycin; dpt, diptericin.
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